Schizophrenia
Conditions
Interventions
medcine intervention group?:adjunctive with 5mg aripiprazole
control group:single risperidone treatment
Sponsors
Shanghai Mental Health Center
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. patients without hyperprolactinemic; 2. All hospitalized schizophrenia patients in acute period were screened by the Structured Clinical Interview for CCMD-3; 3. schizophrenia patients aged 18-45 years; 4. Written informed consent was obtained from each subject or their legal guardians before any study-related procedures were performed.
Exclusion criteria
Exclusion criteria: 1. patients who were pregnant or lactating or planning to pregnancy; 2. patients with serious physical diseases; anomaly laboratory examination results which has clinical significance (such as ALT,AST level = 1.5 times of the normal upper limit); 3. ECG abnormalities with clinical significance; 4. organic mental disorders including mental retardation; Obvious suicidal tendency; 5. drug allergic history such as risperidonepaliperidoneone or aripiprazole; 6. Patients with organic diseases (especially the hypothalamic -pituitary- adrenal axis disease).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| prolactin; | — |
Secondary
| Measure | Time frame |
|---|---|
| Sex hormone; | — |
Countries
China
Contacts
Public ContactQiao Ying
Shanghai Mental Health Center
Outcome results
None listed